Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

Geßner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm M, Schmieder R, Maas R (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Cardiovascular Diabetology BioMed Central

Book Volume: 21

Journal Issue: 1

DOI: 10.1186/s12933-021-01436-x

Abstract

Background: In patients with type 2 diabetes (T2D) sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve glycaemic control as well as cardiovascular and renal outcomes. Their effects on L-arginine (Arg) related risk markers asymmetric and symmetric dimethylarginine (ADMA and SDMA) and the protective biomarker L-homoarginine (hArg) linking T2D to cardiovascular and renal disease have not yet been reported.

Authors with CRIS profile

Arne Geßner Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Martin Fromm Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Roland Schmieder Professur für Innere Medizin (Nephrologie) Renke Maas Professur für Arzneimitteltherapiesicherheit und Klinische Pharmakologie

Involved external institutions

Universitätsklinikum Bonn DE Germany (DE)

How to cite

APA:

Geßner, A., Gemeinhardt, A., Bosch, A., Kannenkeril, D., Staerk, C., Mayr, A.,... Maas, R. (2022). Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular Diabetology, 21(1). https://doi.org/10.1186/s12933-021-01436-x

MLA:

Geßner, Arne, et al. "Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers." Cardiovascular Diabetology 21.1 (2022).

BibTeX: Download